Cirio advises Scandinavian Real Heart on a rights issue

Cirio has advised Scandinavian Real Heart AB (publ) (“Realheart”) in connection with a new issue of shares with pre-emption rights for the company’s shareholders.

Realheart develops a total artificial heart (TAH) for implantation in patients with life-threatening congestive heart failure. Realheart’s TAH has a unique, patented design which consists of a system of four ventricles (two atriums, two ventricles) which provides the possibility of generating a physiologically adapted blood flow that mimics the body’s natural circulation. Realheart is listed on Spotlight Stock Market.

Cirio advised Realheart with a team headed by Per Hedman (Life Science and M&A) and Maria Arnoldsson (Capital Markets and Public M&A), together with Oliver Kronberg and Rebecka Tallberg (Capital Markets and Public M&A), Jessika Lagebro (M&A), and Christopher Tehrani and David Leffler (Intellectual Property).

For more information, please contact: